The risk of COVID-19 infection in patients with atopic dermatitis: A retrospective cohort study - 09/12/21
Doi : 10.1016/j.jaad.2021.09.061
Jashin J. Wu, MD a, ⁎ 
, Amylee Martin, BS b, Jeffrey Liu, BS c, Akshitha Thatiparthi, BS d, Shaokui Ge, PhD b, Alexander Egeberg, MD, PhD e, Jacob P. Thyssen, MD, PhD, DmSci e
, Amylee Martin, BS b, Jeffrey Liu, BS c, Akshitha Thatiparthi, BS d, Shaokui Ge, PhD b, Alexander Egeberg, MD, PhD e, Jacob P. Thyssen, MD, PhD, DmSci e a Dermatology Research and Education Foundation, Irvine, California
b School of Medicine, University of California, Riverside, California
c Keck School of Medicine, University of Southern California, Los Angeles, California
d Western University of Health Sciences, Pomona, California
e Department of Dermatology, Bispebjerg University Hospital, University of Copenhagen, Copenhagen, Denmark
∗Reprint requests: Jashin J. Wu, MD, Dermatology Research and Education Foundation, Irvine, CADermatology Research and Education FoundationIrvineCA
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Key words : atopic dermatitis, COVID-19, dupilumab, epidemiology, infection
| Funding sources: None. |
|
| IRB approval status: Exempt - de-identified data. |
© 2021
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 86 - N° 1
P. 243-245 - janvier 2022 Retour au numéro
Article précédent
- Three years of methotrexate and secukinumab: Outcomes of psoriatic arthritis in a real-life setting
- Stefania Nicola, Silvia Gallo Cassarino, Giovanni Rolla, Giada Geronazzo, Monica Fornero, Luisa Brussino
- Impact of the COVID-19 pandemic on hospitalizations of patients with moderate-to-severe skin diseases: A retrospective cohort analysis from a Central European Center
- Franziska Schauer, Max Behrens, Sabine Mueller, Frank Meiss, Dimitra Kiritsi
Bienvenue sur EM-consulte, la référence des professionnels de santé.